Floatz logo

cc-5013

Peritoneal (Metastatic) Cancer

Sun Yat-sen UniversityPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Peritoneal (Metastatic) Cancer cohort.

Asset / SponsorPhaseRating
Lubiprostone
Sun Yat-sen University
Phase 2CCC
Zanubrutinib
Sun Yat-sen University
Phase 2CCC
Cetuximab
Fudan University
Phase 2CCC
Acm-Cpg
Brown University
Phase 1CC

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →